Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-11 4:22 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Cormorant Asset Management LP | 1,895,717 14.980% | 1,895,717 (New Position) | Filing History |
| 2024-06-20 4:01 pm Purchase | 2024-06-10 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP | Cormorant Asset Management LP | 2,940,283 8.040% | 2,940,283 (New Position) | Filing History |
| 2024-05-13 4:00 pm Purchase | 2024-05-02 | 13G | CytomX Therapeutics, Inc. CTMX | Cormorant Asset Management LP | 5,750,000 7.380% | 5,750,000 (New Position) | Filing History |
| 2024-04-29 4:02 pm Purchase | 2024-04-19 | 13G | TScan Therapeutics, Inc. TCRX | Cormorant Asset Management LP | 2,500,000 5.150% | 2,500,000 (New Position) | Filing History |
| 2024-04-15 6:10 pm Sale | 2024-04-03 | 13G | Immuneering Corporation IMRX | Cormorant Asset Management LP | 1,700,000 5.810% | -2,504,364 (-59.57%) | Filing History |
| 2024-03-21 4:02 pm Purchase | 2024-03-11 | 13G | Ventyx Biosciences, Inc. VTYX | Cormorant Asset Management LP | 3,670,000 5.210% | 3,670,000 (New Position) | Filing History |
| 2024-03-18 4:11 pm Purchase | 2024-03-08 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Cormorant Asset Management LP | 2,025,000 19.300% | 2,025,000 (New Position) | Filing History |
| 2024-02-14 3:08 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | Cormorant Asset Management LP | 746,180 5.820% | 746,180 (New Position) | Filing History |
| 2024-02-14 3:08 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 1,211,696 4.380% | -745,436 (-38.09%) | Filing History |
| 2024-02-14 3:08 pm Purchase | 2023-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA | Cormorant Asset Management LP | 2,456,800 4.490% | 374,800 (+18.00%) | Filing History |
| 2024-02-14 3:07 pm Sale | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Cormorant Asset Management LP | 2,550,000 4.390% | -300,000 (-10.53%) | Filing History |
| 2024-02-14 3:07 pm Purchase | 2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Cormorant Asset Management LP | 3,250,000 5.960% | 450,000 (+16.07%) | Filing History |
| 2024-02-14 3:05 pm Purchase | 2023-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX | Cormorant Asset Management LP | 633,345 7.390% | 633,345 (New Position) | Filing History |
| 2024-02-14 3:04 pm Purchase | 2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 2,221,422 6.710% | 485,000 (+27.93%) | Filing History |
| 2024-02-14 3:04 pm Purchase | 2023-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH | Cormorant Asset Management LP | 2,141,506 9.990% | 339,559 (+18.84%) | Filing History |
| 2024-02-14 3:03 pm Sale | 2023-12-31 | 13G | Korro Bio, Inc. KRRO | Cormorant Asset Management LP | 529,170 6.610% | -150,000 (-22.09%) | Filing History |
| 2024-02-14 3:03 pm Purchase | 2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 11,231,000 17.780% | 11,231,000 (New Position) | Filing History |
| 2024-02-14 3:02 pm Sale | 2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Cormorant Asset Management LP | 0 0.000% | -2,893,717 (Position Closed) | Filing History |
| 2024-02-14 3:02 pm Sale | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | Cormorant Asset Management LP | 0 0.000% | -1,952,032 (Position Closed) | Filing History |
| 2024-02-14 3:01 pm Unchanged | 2023-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN | Cormorant Asset Management LP | 0 0.000% | 0 (Unchanged) | Filing History |